Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Oncolytic Virus Therapy in Metastatic Triple Negative Breast Cancer and Metastatic Non-Small Cell Lung Cancer Followed by Pembrolizumab
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Aglatimagene besadenovec (Primary) ; Pembrolizumab (Primary) ; Valaciclovir (Primary)
- Indications Breast cancer; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms STOMP
- 07 Aug 2017 Status changed from not yet recruiting to recruiting.
- 13 Jun 2017 Planned initiation date changed from 1 May 2017 to 1 Jul 2017.
- 31 Mar 2017 Planned End Date changed from 1 Jul 2023 to 1 Nov 2023.